A 28 year old woman, who is 10 weeks pregnant, is brought to ED with drowsiness and confusion. She has had a persistent fever since recently returning from travelling around India. Microscopic examination of thick and thin blood films demonstrates falciparum malaria with schizonts seen. Which of the following treatments is recommended first line for this patient:
Malaria is an infection of red blood cells caused by a protozoan parasite. Endemic malaria is predominantly found in the tropics and subtropics.
There are four different Plasmodium species relevant in humans:
Some red blood cell defects (e.g. sickle cell disease, thalassaemia and glucose 6-phosphate dehydrogenase deficiency) confer some protection against P. falciparum malaria.
Malaria may be “uncomplicated” or “severe.”
Complications of malaria include:
Malaria should be considered in all acutely unwell or pyrexic travellers returning from endemic areas.
A thick and thin blood film examined by an experienced microscopist and correlated with a clinical history is the gold standard for diagnosis. Diagnosis is made with serial blood film examination - three negative malaria smears 12 - 24 hours apart blood films are required to exclude a diagnosis. Thick blood film is used for malaria diagnosis and thin blood film to diagnose the species of Plasmodium.
Newer, more rapid antigen detection tests may also be used. Antigen dipstick tests are simple but have three main problems:
Classification:
Please note:
FALCIPARUM MALARIA:
Patients with falciparum malaria should usually be admitted to hospital initially due to the risk of rapid deterioration even after starting treatment.
Artemisinin combination therapy is recommended for the treatment of uncomplicated P. falciparum malaria. Artemether with lumefantrine is the drug of choice; artenimol with piperaquine phosphate is a suitable alternative. Oral quinine or atovaquone with proguanil hydrochloride can be used if an artemisinin combination therapy is not available. Quinine is highly effective but poorly-tolerated in prolonged treatment and should be used in combination with an additional drug, usually oral doxycycline.
Severe or complicated falciparum malaria should be managed in a high dependency unit or intensive care setting. Intravenous artesunate (available for ‘named-patient’ use from infectious disease units or specialist tropical disease centres) is indicated in all patients with severe or complicated falciparum malaria, or those at high-risk of developing severe disease (such as if more than 2% of red blood cells are parasitized), or if the patient is unable to take oral treatment. Following a minimum of 24 hours of intravenous artesunate treatment, and when the patient has improved and is able take oral treatment, a full course of artemisinin combination therapy should be given. A full course of oral quinine with doxycycline, or atovaquone with proguanil hydrochloride are suitable alternatives.
Treatment of severe or complicated falciparum malaria should not be delayed whilst obtaining artesunate. Quinine by intravenous infusion should be given if artesunate is not immediately available; it should be continued until the patient can take oral quinine to complete a full course. Oral doxycycline should also be given when the patient can swallow.
In most parts of the world, P. falciparum is now resistant to chloroquine which should not therefore be used for treatment. Mefloquine is also no longer recommended for treatment because of concerns about adverse effects and non-completion of courses.
FALCIPARUM MALARIA IN PREGNANCY:
Falciparum malaria in pregnancy carries a higher risk of severe disease; it requires prompt treatment by specialists in hospital and close observation. Uncomplicated falciparum malaria in the second and third trimesters of pregnancy should be treated with artemether with lumefantrine. Quinine with clindamycin can be used in all trimesters. Quinine can increase the risk of uterine contractions and hypoglycemia.
Severe or complicated falciparum malaria is associated with a high risk of fatality, pregnancy loss, and complications. Due to efficacy, treatment with intravenous artesunate in any trimester of pregnancy is preferred; intravenous quinine (with clindamycin) can be used as an alternative if artesunate is not available.
Is there something wrong with this question? Let us know and we’ll fix it as soon as possible.
Biochemistry | Normal Value |
---|---|
Sodium | 135 – 145 mmol/l |
Potassium | 3.0 – 4.5 mmol/l |
Urea | 2.5 – 7.5 mmol/l |
Glucose | 3.5 – 5.0 mmol/l |
Creatinine | 35 – 135 μmol/l |
Alanine Aminotransferase (ALT) | 5 – 35 U/l |
Gamma-glutamyl Transferase (GGT) | < 65 U/l |
Alkaline Phosphatase (ALP) | 30 – 135 U/l |
Aspartate Aminotransferase (AST) | < 40 U/l |
Total Protein | 60 – 80 g/l |
Albumin | 35 – 50 g/l |
Globulin | 2.4 – 3.5 g/dl |
Amylase | < 70 U/l |
Total Bilirubin | 3 – 17 μmol/l |
Calcium | 2.1 – 2.5 mmol/l |
Chloride | 95 – 105 mmol/l |
Phosphate | 0.8 – 1.4 mmol/l |
Haematology | Normal Value |
---|---|
Haemoglobin | 11.5 – 16.6 g/dl |
White Blood Cells | 4.0 – 11.0 x 109/l |
Platelets | 150 – 450 x 109/l |
MCV | 80 – 96 fl |
MCHC | 32 – 36 g/dl |
Neutrophils | 2.0 – 7.5 x 109/l |
Lymphocytes | 1.5 – 4.0 x 109/l |
Monocytes | 0.3 – 1.0 x 109/l |
Eosinophils | 0.1 – 0.5 x 109/l |
Basophils | < 0.2 x 109/l |
Reticulocytes | < 2% |
Haematocrit | 0.35 – 0.49 |
Red Cell Distribution Width | 11 – 15% |
Blood Gases | Normal Value |
---|---|
pH | 7.35 – 7.45 |
pO2 | 11 – 14 kPa |
pCO2 | 4.5 – 6.0 kPa |
Base Excess | -2 – +2 mmol/l |
Bicarbonate | 24 – 30 mmol/l |
Lactate | < 2 mmol/l |